Maze Therapeutics, Inc.

Maze Therapeutics, Inc.

Biotechnology • Healthcare • South San Francisco, CA, United States • MAZE (NGM)

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

650 850 5070 171 Oyster Point Blvd, South San Francisco, CA 94080, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Maze Therapeutics has jumped more than 80% in 3 months. Its CEO is bullish on what’s to come - CNBC
CNBC • Oct 28
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $2,936,544.00 in Stock - MarketBeat
MarketBeat • Dec 31
Why Maze Therapeutics, Up 55%, Was Shocked By Its Own Test Results - Investor's Business Daily
Investor's Business Daily • Sep 11
We Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth - Yahoo Finance
Yahoo Finance • Dec 22
Guggenheim raises Maze Therapeutics stock price target to $46 on CKD program - Investing.com
Investing.com • Dec 19

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Maze Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Maze Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Maze Therapeutics, Inc. have?
Maze Therapeutics, Inc. has approximately 125 employees.
What industry is Maze Therapeutics, Inc. in?
Maze Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Maze Therapeutics, Inc. a publicly traded company?
Yes, Maze Therapeutics, Inc. is publicly traded under the ticker symbol MAZE on the NGM. The company has a market capitalization of approximately $1.95 billion.
Where is Maze Therapeutics, Inc. headquartered?
Maze Therapeutics, Inc. is headquartered in South San Francisco, CA, United States at 171 Oyster Point Blvd, South San Francisco, CA 94080, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.